Acadian Asset Management
ELTX icon

Acadian Asset Management’s Elicio Therapeutics ELTX Stock Holding History

Acadian Asset Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,380
Closed -$13K – 1777
2023
Q1 		$13K Sell
2,380
-90
-4% -$600 ﹤0.01% 1677
2022
Q4 		$19K Hold
2,470
– – ﹤0.01% 1717
2022
Q3 		$22K Hold
2,470
– – ﹤0.01% 1598
2022
Q2 		$28K Buy
2,470
+1,103
+81% +$17.6K ﹤0.01% 1577
2022
Q1 		$28K Hold
1,367
– – ﹤0.01% 1529
2021
Q4 		$39K Buy
+1,367
New +$69.1K ﹤0.01% 1520

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.53B AUM 30.49% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Acadian Asset Management's ELTX Position: Q2 2023 in Review

Acadian Asset Management sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 2,380 shares — an estimated $13K sold.

Acadian Asset Management first reported a position in ELTX in Q4 2021 and held it in 6 quarters. The position peaked at $39K in Q4 2021. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

  • Acadian Asset Management reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Acadian Asset Management sold 2,380 Elicio Therapeutics shares in Q2 2023, an estimated $13K.
  • Acadian Asset Management first reported a position in Elicio Therapeutics in Q4 2021 and held it in 6 quarters.
  • Acadian Asset Management's Elicio Therapeutics position peaked at $39K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.